03 Aug 2015

VIMOVO modified-release (Naproxen / Esomeprazole) - United Kingdom

ATC: M01AE
MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
PROPIONIC ACID DERIVATIVES
VIMOVO modified-release tablets

Last Updated on 03 Aug 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

VIMOVO modified-release tablets Indication

VIMOVO is indicated in adults for the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID)-associated gastric and/or duodenal ulcers and where treatment with lower doses of naproxen or of other NSAIDs is not considered sufficient.

 

VIMOVO modified-release tablets Generic Name

Naproxen / Esomeprazole

Type

POM

Summary Product Characteristics (SPCs) Links
SPC - VIMOVO 500 mg/20 mg modified-release tablets (external site)

Free Medical Education Resources

VIMOVO modified-release Marketing Information

VIMOVO modified-release Generic Name
Naproxen / Esomeprazole
Marketing Company
AstraZeneca UK Ltd
Drug Type
POM
Date of Issue, Marketing Authority 05/11/2010

Related Drugs - Rheumatology

Back to top